{
  "Country": "FR",
  "PICOs": [
    {
      "Population": "Adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy",
      "Intervention": "New medicine under assessment",
      "Comparator": "Sotorasib (LUMYKRAS)",
      "Outcomes": "Objective response rate, duration of response, disease control rate, delay until response, progression-free survival, overall survival, quality of life, tolerance"
    },
    {
      "Population": "Adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy",
      "Intervention": "New medicine under assessment",
      "Comparator": "Docetaxel",
      "Outcomes": "Objective response rate, duration of response, disease control rate, delay until response, progression-free survival, overall survival, quality of life, tolerance"
    },
    {
      "Population": "Adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy",
      "Intervention": "New medicine under assessment",
      "Comparator": "Ramucirumab + Docetaxel",
      "Outcomes": "Objective response rate, duration of response, disease control rate, delay until response, progression-free survival, overall survival, quality of life, tolerance"
    },
    {
      "Population": "Adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy",
      "Intervention": "New medicine under assessment",
      "Comparator": "Atezolizumab",
      "Outcomes": "Objective response rate, duration of response, disease control rate, delay until response, progression-free survival, overall survival, quality of life, tolerance"
    },
    {
      "Population": "Adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy",
      "Intervention": "New medicine under assessment",
      "Comparator": "Nivolumab",
      "Outcomes": "Objective response rate, duration of response, disease control rate, delay until response, progression-free survival, overall survival, quality of life, tolerance"
    },
    {
      "Population": "Adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy",
      "Intervention": "New medicine under assessment",
      "Comparator": "Gemcitabine + Bevacizumab",
      "Outcomes": "Objective response rate, duration of response, disease control rate, delay until response, progression-free survival, overall survival, quality of life, tolerance"
    }
  ]
}